Relypsa Offers Data Published in New England Journal of Medicine for Pivotal Phase 3 Program of Patiromer FOS

By: via Benzinga
Relypsa, Inc. (Nasdaq: RLYP), a biopharmaceutical company, announced that results from the pivotal Phase 3 program of the company's ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.